1-4 of 4
Ju RueyJiuan Lee, PhD
Close
Sort by
Journal Articles

Clinical Profile of Single-Agent Oprozomib in Patients (Pts) with Multiple Myeloma (MM): Updated Results from a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study

Ravi Vij, MBBS, MD, Michael Savona, MD, David S. Siegel, MD PhD, Jonathan L. Kaufman, MD, Ashraf Badros, MD, Irene M. Ghobrial, MD, Agne Paner, MD, Sundar Jagannath, MD, Andrzej Jakubowiak, MD PhD, Joseph R. Mikhael, MD, Prashant Kapoor, MD, Linda L. Neuman, MD MBA, Ju RueyJiuan Lee, PhD, Jesus G. Berdeja, MD
Journal: Blood
Blood (2014) 124 (21): 34.
https://doi.org/10.1182/blood.V124.21.34.34
Published: 2014
Journal Articles

Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Waldenström Macroglobulinemia (WM)

David S. Siegel, MD PhD, Jonathan L. Kaufman, MD, Noopur S. Raje, MD, Joseph R. Mikhael, MD, Prashant Kapoor, MD, Steven P. Treon, MD PhD, Jorge J. Castillo, MD, Linda L. Neuman, MD MBA, Ju RueyJiuan Lee, PhD, Irene Ghobrial, MD
Journal: Blood
Blood (2014) 124 (21): 1715.
https://doi.org/10.1182/blood.V124.21.1715.1715
Published: 2014
Journal Articles

A Phase 1b Dose-Escalation Study of Split-Dose Oprozomib (ONX0912) in Patients with Hematologic Malignancies

Michael R. Savona, MD, FACP, Jesus G. Berdeja, MD, Susan J Lee, Hansen Wong, PhD, Ju RueyJiuan Lee, PhD, Heidi H. Gillenwater, MD, David S. Siegel, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 203.
https://doi.org/10.1182/blood.V120.21.203.203
Published: 2012
Journal Articles

A Phase 1b Study of 30-Minute Infusion Carfilzomib 20/45 and 20/56 Mg/m 2 Plus 40 Mg Weekly Dexamethasone in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma

Ashraf Z. Badros, MD, Kyriakos P Papadopoulos, MD, Naseem Zojwalla, MD, Ju RueyJiuan Lee, PhD, David S. Siegel, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 4036.
https://doi.org/10.1182/blood.V120.21.4036.4036
Published: 2012